Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $27.4 million.

  • Metagenomi's Cash from Investing Activities rose 40627.94% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.7 million, marking a year-over-year increase of 27782.77%. This contributed to the annual value of -$88.2 million for FY2024, which is 29276.03% down from last year.
  • According to the latest figures from Q3 2025, Metagenomi's Cash from Investing Activities is $27.4 million, which was up 40627.94% from $19.1 million recorded in Q2 2025.
  • Metagenomi's Cash from Investing Activities' 5-year high stood at $75.9 million during Q3 2023, with a 5-year trough of -$94.7 million in Q1 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was $19.1 million (2025), whereas its average is $2.6 million.
  • Per our database at Business Quant, Metagenomi's Cash from Investing Activities crashed by 11177.25% in 2024 and then soared by 40627.94% in 2025.
  • Quarter analysis of 3 years shows Metagenomi's Cash from Investing Activities stood at $60.6 million in 2023, then tumbled by 52.92% to $28.5 million in 2024, then dropped by 4.14% to $27.4 million in 2025.
  • Its Cash from Investing Activities stands at $27.4 million for Q3 2025, versus $19.1 million for Q2 2025 and $24.7 million for Q1 2025.